New hope for aggressive lymphoma: precision therapy trial launches
NCT ID NCT07499271
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial is testing a combination of targeted drugs and chemotherapy in 35 people newly diagnosed with a specific, hard-to-treat form of diffuse large B-cell lymphoma (DLBCL) that has a TP53 mutation. The goal is to see if this precision approach can improve how long patients live without their cancer getting worse. Participants will receive a regimen including polatuzumab vedotin, rituximab, and standard chemotherapy drugs.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, prednisone
What this could lead to
If successful, this could provide a more effective treatment option for a hard-to-treat form of lymphoma, potentially improving survival rates.
What could go wrong
This is a small, early-phase trial with only 35 participants, so results may not apply broadly. The treatment involves chemotherapy drugs with known side effects like infection and heart damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Soochow University
RECRUITINGSuzhou, Jiangsu, 215006, China
Contact Phone: •••-•••-•••• Email: •••••@•••••